id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_dckvto3egvg45mviujasr54q7y	Anuj Agarwala	Gefitinib Plus Celecoxib in Chemotherapy-Naïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: A Phase II Study from the Hoosier Oncology Group	2008	6	.pdf	application/pdf	5134	469	60	Gefitinib Plus Celecoxib in Chemotherapy-Naïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: A Phase II Study from the Hoosier Oncology Group Key Words: Non-small cell lung cancer, Gefitinib, Celecoxib. these patients will have non-small cell lung cancer (NSCLC) NSCLC reported response rates of 11.8% and18.4%, respectively.8,9 Substantially more patients achieved stable disease study was to estimate the overall response rate of the combination of gefitinib plus celecoxib in this patient population. patients with non-small cell cancer: a randomized trial. gefitinib in patients with advanced non-small cell lung cancer: a phase ii patients with untreated advanced non-small cell lung cancer and poor treatment of patients with advanced non-small-cell lung cancer: A advanced non-small cell lung cancer (NSCLC) patients treated with Gefitinib Plus Celecoxib in Chemotherapy-Naı¨ve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: A Phase II Study from the Hoosier Oncology Group	./cache/work_dckvto3egvg45mviujasr54q7y.pdf	./txt/work_dckvto3egvg45mviujasr54q7y.txt